Zacks: Brokerages Anticipate Galapagos NV (NASDAQ:GLPG) to Post -$1.67 EPS

Analysts forecast that Galapagos NV (NASDAQ:GLPG) will report earnings of ($1.67) per share for the current quarter, Zacks reports. Two analysts have made estimates for Galapagos’ earnings. The lowest EPS estimate is ($2.58) and the highest is ($1.19). Galapagos reported earnings per share of ($1.46) in the same quarter last year, which indicates a negative year-over-year growth rate of 14.4%. The firm is scheduled to announce its next earnings report on Thursday, November 4th.

On average, analysts expect that Galapagos will report full-year earnings of ($4.45) per share for the current fiscal year, with EPS estimates ranging from ($5.49) to ($3.40). For the next financial year, analysts forecast that the firm will post earnings of ($4.35) per share, with EPS estimates ranging from ($8.26) to ($0.95). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Galapagos.

Galapagos (NASDAQ:GLPG) last released its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($1.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.24. Galapagos had a negative net margin of 34.21% and a negative return on equity of 8.38%. The company had revenue of $184.41 million for the quarter, compared to analysts’ expectations of $97.71 million.

A number of analysts have weighed in on GLPG shares. UBS Group reissued a “neutral” rating on shares of Galapagos in a report on Friday, August 27th. Deutsche Bank Aktiengesellschaft lowered shares of Galapagos from a “buy” rating to a “hold” rating and set a $50.00 target price on the stock. in a research report on Friday, August 6th. Raymond James set a $65.80 target price on shares of Galapagos and gave the stock a “buy” rating in a research report on Thursday, July 15th. Barclays lowered shares of Galapagos from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 19th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Galapagos in a research report on Wednesday, August 11th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Galapagos has an average rating of “Hold” and an average price target of $98.42.

GLPG stock traded up $0.44 during midday trading on Friday, reaching $54.53. 5,662 shares of the company were exchanged, compared to its average volume of 290,855. Galapagos has a 1-year low of $48.66 and a 1-year high of $145.59. The stock’s 50-day simple moving average is $56.08 and its 200 day simple moving average is $66.99. The company has a market cap of $3.57 billion, a price-to-earnings ratio of -10.16 and a beta of 0.54.

Large investors have recently bought and sold shares of the stock. OLD Mission Capital LLC boosted its position in shares of Galapagos by 290.1% during the 3rd quarter. OLD Mission Capital LLC now owns 113,719 shares of the biotechnology company’s stock worth $16,138,000 after purchasing an additional 84,569 shares in the last quarter. The PNC Financial Services Group Inc. boosted its position in shares of Galapagos by 936.4% during the 1st quarter. The PNC Financial Services Group Inc. now owns 342 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 309 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Galapagos during the 1st quarter worth $1,086,000. Standard Family Office LLC purchased a new stake in shares of Galapagos during the 1st quarter worth $33,000. Finally, Geode Capital Management LLC boosted its position in shares of Galapagos by 4.8% during the 1st quarter. Geode Capital Management LLC now owns 4,820 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 11.27% of the company’s stock.

Galapagos Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Featured Article: How does inflation affect different investments?

Get a free copy of the Zacks research report on Galapagos (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.